Aduro BioTech Inc (NASDAQ:ADRO) insider Natalie Sacks sold 4,504 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $7.13, for a total value of $32,113.52. Following the transaction, the insider now owns 89,548 shares in the company, valued at $638,477.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Aduro BioTech stock traded down $0.85 during trading on Friday, reaching $7.00. The company’s stock had a trading volume of 16,800 shares, compared to its average volume of 272,699. The stock has a market capitalization of $620.62 million, a price-to-earnings ratio of -5.48 and a beta of 2.23. Aduro BioTech Inc has a 1-year low of $5.10 and a 1-year high of $11.95.

Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $2.64 million during the quarter, compared to analysts’ expectations of $3.74 million. Aduro BioTech had a negative return on equity of 44.97% and a negative net margin of 574.11%. equities research analysts forecast that Aduro BioTech Inc will post -1.17 EPS for the current year.

ADRO has been the topic of a number of analyst reports. Zacks Investment Research downgraded Aduro BioTech from a “buy” rating to a “hold” rating in a report on Wednesday, July 4th. BidaskClub upgraded Aduro BioTech from a “strong sell” rating to a “sell” rating in a report on Friday, August 31st. HC Wainwright set a $10.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Thursday, August 2nd. Bank of America cut their price target on Aduro BioTech from $8.00 to $6.00 and set an “underperform” rating on the stock in a report on Thursday, August 2nd. Finally, ValuEngine upgraded Aduro BioTech from a “strong sell” rating to a “sell” rating in a report on Friday, June 1st. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $13.67.

Several institutional investors have recently bought and sold shares of the company. Swiss National Bank boosted its position in shares of Aduro BioTech by 14.3% in the 1st quarter. Swiss National Bank now owns 57,500 shares of the biotechnology company’s stock worth $535,000 after purchasing an additional 7,200 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Aduro BioTech by 105.3% in the 1st quarter. Legal & General Group Plc now owns 22,233 shares of the biotechnology company’s stock worth $206,000 after purchasing an additional 11,405 shares in the last quarter. MetLife Investment Advisors LLC boosted its position in shares of Aduro BioTech by 70.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 31,799 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 13,156 shares in the last quarter. Alps Advisors Inc. boosted its position in shares of Aduro BioTech by 14.2% in the 2nd quarter. Alps Advisors Inc. now owns 114,257 shares of the biotechnology company’s stock worth $800,000 after purchasing an additional 14,187 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Aduro BioTech by 10.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 164,071 shares of the biotechnology company’s stock worth $1,526,000 after purchasing an additional 14,863 shares in the last quarter. 49.01% of the stock is owned by hedge funds and other institutional investors.

Aduro BioTech Company Profile

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Featured Story: Google Finance Portfolio

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.